

PTO/SB/08B (07-05) Approved for use through 07/31/2006, OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete If Known Substitute for form 1449/PTO **Application Number** 10/517,319 INFORMATION DISCLOSURE Filing Date July 15, 2005 STATEMENT BY APPLICANT First Named Inventor Philippe A. TESSIER Art Unit 1644 (Use as many sheets as necessary) Examiner Name Sharon Marsha M. TSAY wen Attorney Docket Number Sheet 6013-149US

		NON PATENT LITERATURE DOCUMENTS	r
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
/S.W./		DONATO, Rosario: "Functional roles of S100 proteins, calclum-binding proteins of the EF-hand type" Biochimica et Biophysica Acta 1450 (1999), pages 191-231	
/S.W./		RAVASI, Timothy et al.: "Probing the S100 protein family through genomic and functional analysis" Genomics 84 (2004), pages 10-22	
		·	
		·	
	_	·	

Examiner	9	Date	
Signature	/Sharon Wen/	Considered	08/15/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (opsional). 2 Applicant is to place a check merk here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Petern and Tradement Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTC/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete If Known
, 0.333333 0. 0. 0. 111111111111111111111	Application Number	10/517,319
INFORMATION DISCLOSURE	Filing Date	July 15, 2005
STATEMENT BY APPLICANT	First Named Inventor	Philippe A. TESSIER
(Use as many sheets as necessary)	Art Unit	<del>1650.</del> /644
food as tituing orders as tracessary	Examiner Name	Marsha M. TSAY Sharon Wen
Sheet 1 of 1	Attorney Docket Number	6013-149US

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T <sup>2</sup>
	110.	number(s), publisher, city and/or country where published.	
/S.W./		Mauro PERRETTI et al., Mobilizing Lipocortin 1 in adherent human leukocytes downregulates their transmigration, Nat Medicine, 1996, 2: 1259-1262	
· · · · · · · · · · · · · · · · · · ·			

		<del></del>	
Examiner	/Sharon Wen/	Date	00/45/2007
Signature	/Sharon Wen/	Considered	08/15/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial in reference considered, whether of not citation is in conformance with MPEP 809. Draw late through citation a not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known			
Separate for form	443/10		Application Number	10/517,319		
INFORMA	TION DIS	CLOSURE	Filing Date	July 15, 2005		
STATEMENT BY APPLICANT			First Named Inventor	Philippe A. TESSII	ER	
			Art Unit	<del>1956</del> -	1644	
(Use as many sheets as necessary)			Examiner Name	TSAY, Marcha M	Sharon Wen	
Sheet 1 of 1			Attorney Docket Number	6013-149US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
/S.W./		EUE et al., Transendothelial migration of 27E10+ human monocytes, International Immunology, 2000, Vol. 12: 1593-1604	
/S.W./		HARRISON et al., Oxidation Regulates the Inflammatory Properties of the Murine S100 Protein S100A8, The Journal of Biological Chemistry, 1999, Vol.274: 8561-8569	
/S.W./		NEWTON et al., The Human S100 Protein MRP-14 Is a Novel Activator of the β2 Integrin Mac-1 on Neutrophils, The Journal of Immunology, 1998, 160: 1427-1435	
•			
		·	

The second secon		
Examiner /Sharon Won/	Date	08/15/2007
Signature   /Sharon Wen/	Considered	00/13/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drew line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, prepering, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademerk Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A/B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A and B/PTO INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known						
Application Number	10/517,319					
Filing Date	07/15/2005					
First Named Inventor	Philippe Tessier					
Art Unit	1653					
Examiner Name	·					
Attorney Docket Number	6013-149US MG/pd					

			U.S. PATEN	T DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number - Kind Code <sup>2</sup> (it known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Unes Where Relavant Passages or Relevant Figures Appear
		US 5,731,166	03/24/1998	Geczy Carolyn et al.	
		US 6,103,497	08/15/2000	Corley Neil et al.	
		1			
				·	

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Cite Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines	$\Box$
Initials*	No.1	Country Code3 - Number4 - Kind Code5'(# known)	MM-DD-YYYY	Applicant Of Cited Document	Where Relevant Passages or Relevant Figures Appear	r
		EP 0,263,072	04/06/1988	Ciba Geigy Ag		
	<u> </u>		<u> </u>			╄
	<del>                                     </del>					╁
						$\top$
				· · · · · · · · · · · · · · · · · · ·		
						<u> </u>
	-					╄
	-					╁╾
			<del></del>			$\vdash$
			]			1

1TO/SB/08A/B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known Substitute for form 1449A and B/PTO Application Number 10/517,319 INFORMATION DISCLOSURE 07/15/2005 Filing Date First Named Inventor Philippe Tessler STATEMENT BY APPLICANT Art Unit (use as many sheets as necessary) Sharon **Examiner Name** 6013-149US MG/pd of **Attorney Docket Number** 

			OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exar er Initia	-	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
/S	3.W	'. <i>I</i>	DUNN C J ET AL: "Increased expression of neutrophil MRP8 and MRP14 is associated with vascular adhesion molecule activation and differential leukocyte infiltration in delayed-type hypersensitivity suggesting a proinflammatory role for S100 calcium-binding proteins" Biosis, XP002242712 abstract	
			YEN TINA ET AL: "Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli", Blood, W.B. Saunders, Philadelphia, VA, US, vol. 90, no. 12, 15 December 1997, pages 4812-4821	
			LAGASSE E ET AL: "Mouse MRP8 and MRP14, two intracellular calcium-binding proteins associated with the development of the myeloid lineage" Blood, W.B. Saunders, Philadelphia, VA, US, vol. 79, 1992, pages 1907-1915	
			LACKMANN M.: "Identification of a chemotactic domain of the pro-inflammatory S100 Protein CP-10", Journal of immunology, The Williams and Wilkins Co. Baltimore, US, vol. 150, no 7, April 1, 1993, pages 2981-2991	
			DEVERY JANNINE M ET AL: "Acute inflammatory activity of the S100 protein CP-10: Activation of neutrophils in vivo and in vitro." Journal of immunology, vol. 152, no. 4, 1994, pages 1888-1897	
			RYCKMAN CARLE ET AL: "Proinflammatory activities of S100: Proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion." Journal of immunology, vol. 170, no. 6, 15 March 2003, pages 3233-3242	
V	/		ROULEAU PASCAL ET AL: "The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis., Clinical immunology (Orlando), vol. 107, no.1, 20 April 2003, pages 46-54	

Examiner Signature	/Sharon Wen/	Date Considered	08/15/2007

<sup>\*</sup>EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.